Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up – Time to Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) gapped up prior to trading on Friday . The stock had previously closed at $29.90, but opened at $32.25. Dianthus Therapeutics shares last traded at $30.56, with a volume of 27,707 shares.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Oppenheimer began coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 target price for the company. Finally, Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $45.14.

Dianthus Therapeutics Price Performance

The company has a market capitalization of $853.20 million, a price-to-earnings ratio of -5.40 and a beta of 1.84. The business has a fifty day moving average price of $27.75 and a 200 day moving average price of $26.45.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC bought a new position in Dianthus Therapeutics during the first quarter worth about $89,761,000. RA Capital Management L.P. acquired a new position in shares of Dianthus Therapeutics in the 1st quarter worth approximately $69,990,000. Great Point Partners LLC lifted its position in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after buying an additional 132,929 shares during the period. Vanguard Group Inc. boosted its stake in Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after buying an additional 384,182 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in Dianthus Therapeutics in the first quarter valued at $11,251,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.